|
1
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar
|
|
3
|
Singer EA, Gupta GN and Srinivasan R:
Update on targeted therapies for clear cell renal cell carcinoma.
Curr Opin Oncol. 23:283–289. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheung CW, Gibbons N, Johnson DW and Nicol
DL: Silibinin-a promising new treatment for cancer. Anticancer
Agents Med Chem. 10:186–195. 2010. View Article : Google Scholar
|
|
5
|
Zeng J, Liu W, Fan YZ, He DL and Li L:
PrLZ increases prostate cancer docetaxel resistance by inhibiting
LKB1/AMPK-mediated autophagy. Theranostics. 8:109–123. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li F, Sun Y, Jia J, Yang C, Tang X, Jin B,
Wang K, Guo P, Ma Z, Chen Y, et al: Silibinin attenuates TGF β1
induced migration and invasion via EMT suppression and is
associated with COX2 downregulation in bladder transitional cell
carcinoma. Oncol Rep. 40:3543–3550. 2018.PubMed/NCBI
|
|
7
|
Dheeraj A, Rigby CM, O’Bryant CL, Agarwal
C, Singh RP, Deep G and Agarwal R: Silibinin treatment inhibits the
growth of Hedgehog inhibitor-resistant basal cell carcinoma cells
via targeting EGFR-MAPK-Akt and Hedgehog signaling. Photochem
Photobiol. 93:999–1007. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rigby CM, Roy S, Deep G, Guillermo-Lagae
R, Jain AK, Dhar D, Orlicky DJ, Agarwal C and Agarwal R: Role of
p53 in silibinin-mediated inhibition of ultraviolet B
radiation-induced DNA damage, inflammation and skin carcinogenesis.
Carcinogenesis. 38:40–50. 2017. View Article : Google Scholar :
|
|
9
|
Deep G, Kumar R, Nambiar DK, Jain AK,
Ramteke AM, Serkova NJ, Agarwal C and Agarwal R: Silibinin inhibits
hypoxia-induced HIF-1alpha-mediated signaling, angiogenesis and
lipogenesis in prostate cancer cells: In vitro evidence and in vivo
functional imaging and metabolomics. Mol Carcinog. 56:833–848.
2017. View
Article : Google Scholar
|
|
10
|
Ting H, Deep G, Kumar S, Jain AK, Agarwal
C and Agarwal R: Beneficial effects of the naturally occurring
flavonoid silibinin on the prostate cancer microenvironment: Role
of monocyte chemotactic protein-1 and immune cell recruitment.
Carcinogenesis. 37:589–599. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bosch-Barrera J and Menendez JA: Silibinin
and STAT3: A natural way of targeting transcription factors for
cancer therapy. Cancer Treat Rev. 41:540–546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang
T, Zhang L, Chen Y, Gao Y, Wang B, et al: Silibinin inhibits
beta-catenin/ZEB1 signaling and suppresses bladder cancer
metastasis via dual-blocking epithelial-mesenchymal transition and
stemness. Cell Signal. 25:2625–2633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Raina K, Agarwal C, Wadhwa R, Serkova NJ
and Agarwal R: Energy deprivation by silibinin in colorectal cancer
cells: A double-edged sword targeting both apoptotic and autophagic
machineries. Autophagy. 9:697–713. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang
Z, Wang Z, Zhang D, Xue Y, Chen Y, et al: Chemopreventive and
chemotherapeutic effects of intravesical silibinin against bladder
cancer by acting on mitochondria. Mol Cancer Ther. 10:104–116.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li L, Zeng J, Gao Y and He D: Targeting
silibinin in the antiproliferative pathway. Expert Opin Investig
Drugs. 19:243–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cui W, Gu F and Hu KQ: Effects and
mechanisms of silibinin on human hepatocellular carcinoma
xenografts in nude mice. World J Gastroenterol. 15:1943–1950. 2019.
View Article : Google Scholar
|
|
17
|
Liang L, Li L, Zeng J, Gao Y, Chen YL,
Wang ZQ, Wang XY, Chang LS and He D: Inhibitory effect of silibinin
on EGFR signal-induced renal cell carcinoma progression via
suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep.
28:999–1005. 2012.PubMed/NCBI
|
|
18
|
Li F, Ma Z, Guan Z, Chen Y, Wu K, Guo P,
Wang X, He D and Zeng J: Autophagy induction by silibinin
positively contributes to its anti-metastatic capacity via
AMPK/mTOR pathway in renal cell carcinoma. Int J Mol Sci.
16:8415–8429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smith BN and Bhowmick NA: Role of EMT in
metastasis and therapy resistance. J Clin Med. 5:E172016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Piva F, Giulietti M, Santoni M, Occhipinti
G, Scarpelli M, Lopez-Beltran A, Cheng L, Principato G and
Montironi R: Epithelial to mesenchymal transition in renal cell
carcinoma: Implications for cancer therapy. Mol Diagn Ther.
20:111–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsuda T: Extracellular interactions
between fibulins and transforming growth factor (TGF)-β in
physiological and pathological conditions. Int J Mol Sci.
19:27872018. View Article : Google Scholar
|
|
22
|
Xu Q, Krause M, Samoylenko A and Vainio S:
Wnt signaling in renal cell carcinoma. Cancers (Basel). 8:572016.
View Article : Google Scholar
|
|
23
|
Petherick KJ, Williams AC, Lane JD,
Ordonez-Moran P, Huelsken J, Collard TJ, Smartt HJ, Batson J, Malik
K, Paraskeva C and Greenhough A: Autolysosomal β-catenin
degradation regulates Wnt-autophagy-p62 crosstalk. Embo J.
32:1903–1916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jia Z, Wang J, Wang W, Tian Y, XiangWei W,
Chen P, Ma K and Zhou C: Autophagy eliminates cytoplasmic
beta-catenin and NICD to promote the cardiac differentiation of
P19CL6 cells. Cell Signal. 26:2299–2305. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grigore AD, Jolly MK, Jia D, Farach-Carson
MC and Levine H: Tumor Budding: The Name is EMT. Partial EMT J Clin
Med. 5:512016. View Article : Google Scholar
|
|
26
|
Saitoh M: Involvement of partial EMT in
cancer progression. J Biochem. 164:257–264. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mowers EE, Sharifi MN and Macleod KF:
Autophagy in cancer metastasis. Oncogene. 36:1619–1630. 2017.
View Article : Google Scholar :
|
|
29
|
Levy J, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Smith AG and Macleod KF: Autophagy, cancer
stem cells and drug resistance. J Pathol. 247:708–718. 2019.
View Article : Google Scholar :
|
|
32
|
Das CK, Mandal M and Kögel D: Pro-survival
autophagy and cancer cell resistance to therapy. Cancer Metastasis
Rev. 37:749–766. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guillen-Ahlers H: Wnt signaling in renal
cancer. Curr Drug Targets. 9:591–600. 2008. View Article : Google Scholar : PubMed/NCBI
|
